Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 15/2016

01-10-2016 | Adis Drug Evaluation

Intravenous Minocycline: A Review in Acinetobacter Infections

Authors: Sarah L. Greig, Lesley J. Scott

Published in: Drugs | Issue 15/2016

Login to get access

Abstract

Intravenous minocycline (Minocin®) is approved in the USA for use in patients with infections due to susceptible strains of Gram-positive and Gram-negative pathogens, including infections due to Acinetobacter spp. Minocycline is a synthetic tetracycline derivative that was originally introduced in the 1960s. A new intravenous formulation of minocycline was recently approved and introduced to address the increasing prevalence of multidrug-resistant (MDR) pathogens. Minocycline shows antibacterial activity against A. baumannii clinical isolates worldwide, and exhibits synergistic bactericidal activity against MDR and extensively drug-resistant (XDR) A. baumannii isolates when combined with other antibacterial agents. In retrospective studies, intravenous minocycline provided high rates of clinical success or improvement and was generally well tolerated among patients with MDR or carbapenem-resistant A. baumannii infections. While randomized clinical trial data would be useful to fully establish the place of minocycline in the management of these infections for which there are currently very few available options, clinical trials in patients with infections due to Acinetobacter spp. are difficult to perform. Nevertheless, current data indicate a potential role for intravenous minocycline in the treatment of patients MDR A. baumannii infections, particularly when combined with a second antibacterial agent (e.g. colistin).
Literature
1.
Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.CrossRefPubMed
2.
3.
Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs. 2014;74(12):1315–33.CrossRefPubMedPubMedCentral
4.
5.
Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014;59(Suppl 6):S374–80.CrossRefPubMed
6.
Bishburg E, Bishburg K. Minocycline—an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob Agents. 2009;34(5):395–401.CrossRefPubMed
7.
Colton B, McConeghy KW, Schreckenberger PC, et al. I.V. minocycline revisited for infections caused by multidrug-resistant organisms. Am J Health Syst Pharm. 2016;73(5):279–85.CrossRefPubMed
8.
9.
10.
Zilberberg MD, Kollef MH, Shorr AF. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: a survey study. J Hosp Med. 2016;11(1):21–6.CrossRefPubMed
11.
Tärnberg M, Nilsson LE, Dowzicky MJ. Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the tigecycline evaluation and surveillance trial (T.E.S.T.), 2010-2014. Int J Infect Dis. 2016;49:141–8.CrossRefPubMed
12.
Hoban DJ, Reinert RR, Bouchillon SK, et al. Global in vitro activity of tigecycline and comparator agents: tigecycline evaluation and surveillance trial 2004–2013. Ann Clin Microbiol Antimicrob. 2015;14(1):27.CrossRefPubMedPubMedCentral
13.
Bouchillon SK, Hackel M, Hoban D, et al. Evaluating multi-drug resistant Acinetobacter baumannii in critical care units [abstract no. K9 plus poster]. Am J Respir Crit Care Med. 2011;183:A5830.
14.
Kehl SC, Dowzicky MJ. Global assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the tigecycline evaluation and surveillance trial. J Clin Microbiol. 2015;53(4):1286–93.CrossRefPubMedPubMedCentral
15.
Denys GA, Callister SM, Dowzicky MJ. Antimicrobial susceptibility among Gram-negative isolates collected in the USA between 2005 and 2011 as part of the tigecycline evaluation and surveillance trial (T.E.S.T.). Ann Clin Microbiol Antimicrob. 2013;12:24.CrossRefPubMedPubMedCentral
16.
Castanheira M, Mendes RE, Jones RN. Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. Clin Infect Dis. 2014;59(Suppl 6):S367–73.CrossRefPubMed
17.
Flamm RK, Castanheira M, Streit JM, et al. Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia and Burkholderia cepacia species complex isolates from a global surveillance program (2013). Diagn Microbiol Infect Dis. 2016;85(3):352–5.CrossRefPubMed
18.
19.
Sahm D, Biedenbach D, Leister-Tebbe H. Antimicrobial susceptibility profiles for multi-drug resistant (MDR) Acinetobacter spp: a global perspective (TEST 2011–2014) [abstract no. C-1016 plus poster]. In: ICAAC. 2015.
20.
Bowker KE, Noel AR, Tomaselli SG, et al. Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection [abstract no. A040]. In: ICAAC. 2014.
21.
Bowers DR, Cao H, Zhou J, et al. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59(5):2720–5.CrossRefPubMedPubMedCentral
22.
He S, He H, Chen Y, et al. In vitro and in vivo analysis of antimicrobial agents alone and in combination against multi-drug resistant Acinetobacter baumannii. Front Microbiol. 2015;6:507.PubMedPubMedCentral
23.
Rodriguez CH, Nastro M, Vay C, et al. In vitro activity of minocycline alone or in combination in multidrug-resistant Acinetobacter baumannii isolates. J Med Microbiol. 2015;64(10):1196–200.CrossRefPubMed
24.
Liang W, Liu XF, Huang J, et al. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect Dis. 2011;11:109.CrossRefPubMedPubMedCentral
25.
Yang YS, Lee Y, Tseng KC, et al. In vivo and in vitro efficacy of minocycline-based combination therapy for minocycline-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(7):4047–54.CrossRefPubMed
26.
Tarazi Z, Sabet M, Dudley MN, et al. Pharmacodynamics of minocycline against Acinetobacter baumannii in a rat pneumonia model [abstract]. In: ICAAC. 2015.
27.
Zhou J, Ledesma KR, Tam VH. In vivo efficacy of minocycline for infections caused by Acinetobacter baumannii [abstract]. In: ICAAC. 2015.
28.
Vilacoba E, Almuzara M, Gulone L, et al. Emergence and spread of plasmid-borne tet(B):ISCR2 in minocycline-resistant Acinetobacter baumannii isolates. Antimicrob Agents Chemother. 2013;57(1):651–4.CrossRefPubMedPubMedCentral
29.
Vilacoba E, Almuzara M, Gulone L, et al. Widespread dispersion of the resistance element tet(B):ISCR2 in XDR Acinetobacter baumannii isolates. Epidemiol Infect. 2016;144(7):1574–8.CrossRefPubMed
30.
Rumbo C, Gato E, Lόpez M, et al. Contribution of efflux pumps, porins, and β-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2013;57(11):5247–57.CrossRefPubMedPubMedCentral
31.
Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Accumulation of several chromosomal mutations have limited impact on the sensitivity of Acinetobacter baumannii (ACB) to minocycline (MINO) [abstract no. C-1009 plus poster]. In: ICAAC. 2015.
32.
Lomovskaya O, Sun D, King P, et al. Tigecycline (TIG) but not minocycline (MINO) readily selects for clinically relevant efflux-mediated resistance (R) in Acinetobacter spp. (ACB) [abstract no. C1-1087 plus poster]. In: ICAAC. 2013.
33.
Jacobs AC, Sayood K, Olmsted SB, et al. Characterization of the Acinetobacter baumannii growth phase-dependent and serum responsive transcriptomes. FEMS Immunol Med Microbiol. 2012;64(3):403–12.CrossRefPubMed
34.
Blanchard C, Barnett P, Perlmutter J, et al. Identification of Acinetobacter baumannii serum-associated antibiotic efflux pump inhibitors. Antimicrob Agents Chemother. 2014;58(11):6360–70.CrossRefPubMedPubMedCentral
35.
Goff DA, Bauer KA, Mangino JE. Bad bugs need old drugs: a stewardship program’s evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections. Clin Infect Dis. 2014;59(Suppl 6):S381–7.CrossRefPubMed
36.
Bishburg E, Shah M, Chan T. Use of intravenous minocycline for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) and resistant Gram-negative organisms: experience in a tertiary care hospital. Infect Dis Clin Pract. 2014;22(1):26–31.CrossRef
37.
Wood GC, Hanes SD, Boucher BA, et al. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive Care Med. 2003;29(11):2072–6.CrossRefPubMed
38.
Pogue JM, Neelakanta A, Mynatt RP, et al. Carbapenem-resistance in Gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. Clin Infect Dis. 2014;59(Suppl 6):S388–93.CrossRefPubMed
39.
Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med. 2010;25(6):343–8.CrossRefPubMed
40.
Jankowski CA, Balada-Llasat JM, Raczkowski M, et al. A stewardship approach to combating multidrug-resistant acinetobacter baumannii infections with minocycline. Infect Dis Clin Pract. 2012;20(3):184–7.CrossRef
41.
Falagas ME, Vardakas KZ, Kapaskelis A, et al. Tetracyclines for multidrug-resistant Acinetobacter baumannii infections. Int J Antimicrob Agents. 2015;45(5):455–60.CrossRefPubMed
42.
Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27(9):1329–42.CrossRefPubMed
43.
Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016. doi:10.​1093/​cid/​ciw353.
44.
Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580–637.CrossRefPubMed
45.
Neonakis IK, Spandidos DA, Petinaki E. Is minocycline a solution for multidrug-resistant Acinetobacter baumannii? Future Microbiol. 2014;9(3):299–305.CrossRefPubMed
Metadata
Title
Intravenous Minocycline: A Review in Acinetobacter Infections
Authors
Sarah L. Greig
Lesley J. Scott
Publication date
01-10-2016
Publisher
Springer International Publishing
Published in
Drugs / Issue 15/2016
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-016-0636-6

Other articles of this Issue 15/2016

Drugs 15/2016 Go to the issue

Adis Drug Evaluation

Apixaban: A Review in Venous Thromboembolism

Adis Drug Evaluation

Calcipotriol/Betamethasone Dipropionate Foam: A Review in Plaque Psoriasis

Leading Article

Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients

Adis Drug Evaluation

Sumatriptan Nasal Powder: A Review in Acute Treatment of Migraine

Current Opinion

Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects

Review Article

Patient-Centered Interventions to Improve Adherence to Statins: A Narrative Synthesis of Systematically Identified Studies